Patents by Inventor Masaaki Odomi
Masaaki Odomi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method
Patent number: 8871818Abstract: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.Type: GrantFiled: October 21, 2008Date of Patent: October 28, 2014Assignees: Otsuka Pharmaceutical Co., Ltd.Inventors: Akira Tsuji, Ikumi Tamai, Yoshimichi Sai, Masaaki Odomi, Hidekazu Toyobuku -
Publication number: 20100331421Abstract: The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt and and a cyclodextrin.Type: ApplicationFiled: September 3, 2010Publication date: December 30, 2010Applicant: Otsuka Pharmaceutical Co., Ltd.Inventors: Toru Nishibayashi, Tetsuya Sato, Masaaki Odomi, Kinue Ohguro, Hiroshi Ishikawa
-
GASTROINTESTINAL ABSORPTION ENHANCER MEDIATED BY PROTON-COUPLED TRANSPORTER AND ITS PREPARING METHOD
Publication number: 20090048350Abstract: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.Type: ApplicationFiled: October 21, 2008Publication date: February 19, 2009Applicants: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Akira Tsuji, Ikumi Tamai, Yoshimichi Sai, Masaaki Odomi, Hidekazu Toyobuku -
Gastrointestinal Absorption Enhancer Mediated By Proton-Coupled Transporter and Its Preparing Method
Publication number: 20080119568Abstract: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.Type: ApplicationFiled: January 9, 2008Publication date: May 22, 2008Inventors: Akira TSUJI, Ikumi Tamai, Yoshimichi Sai, Masaaki Odomi, Hidekazu Toyobuku -
Publication number: 20070053942Abstract: The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt, and at least one polyoxyethylene-based nonionic surfactant selected from the group consisting of polyoxyethylene higher alkyl ethers and polyoxyethylene alkylphenyl ethers; a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt at a concentration of 0.05 to 0.5 W/V %, and an alcohol at a concentration of 20 to 80 W/V %, and not containing any surfactants; and a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt, and at least one member selected from the group consisting of ester-based nonionic surfactants and cyclic oligosaccharides.Type: ApplicationFiled: May 25, 2004Publication date: March 8, 2007Inventors: Toru Nishibayashi, Tetsuya Sato, Masaaki Odomi, Kinue Ohguro, Hiroshi Ishikawa
-
Publication number: 20060121107Abstract: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.Type: ApplicationFiled: January 8, 2004Publication date: June 8, 2006Inventors: Akira Tsuji, Ikumi Tamai, Yoshimichi Sai, Masaaki Odomi, Hidekazu Toyobuku
-
Publication number: 20030045481Abstract: The invention provides an amino acid usable for reducing and/or preventing the coloration caused by a combined use of saccharide and amino acid, and an amino acid usable as a stabilizer for a dry composition containing a pharmacologically active proteinaceous substance. The invention also provides an anti-coloring agent containing a hydrophobic amino acid as an essential ingredient suitable for preventing the coloration of a dry composition containing a saccharide, a method for preventing the coloration of a dry composition containing a saccharide using a hydrophobic amino acid, and a dry composition containing a pharmacologically active proteinaceous substance which further comprises a saccharide and a hydrophpbic amino acid as a stabilizer.Type: ApplicationFiled: June 19, 2002Publication date: March 6, 2003Inventors: Chikamasa Yamashita, Masaaki Odomi
-
Patent number: 6479048Abstract: Provisions of a foam inhibitor which effectively inhibits foaming (bubbling) caused at the time of dissolving dry compositions and of a water-soluble dry composition which comprises the foam inhibitor. The form inhibitor is suitable for inhibiting foaming caused at the time of dissolving dry compositions comprising saccharide which contain a hydrophobic amino acid as essential ingredient; and the water-soluble dry composition contains pharmacologically active proteinaceous substance, saccharide and hydrophobic amino acid having the hydropathy index of about not less than 2, wherein the concentration of the hydrophobic amino acid is in the range of 0.05 wt. % to less than 40 wt. % based on the total amount of the dry composition.Type: GrantFiled: July 12, 2001Date of Patent: November 12, 2002Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Chikamasa Yamashita, Masaaki Odomi
-
Patent number: 6337067Abstract: Provisions of a foam inhibitor which effectively inhibits foaming (bubbling) caused at the time of dissolving dry compositions and of a water-soluble dry composition which comprises the foam inhibitor. The form inhibitor is suitable for inhibiting foaming caused at the time of dissolving dry compositions comprising saccharide which contain a hydrophobic amino acid as essential ingredient; and the water-soluble dry composition contains pharmacologically active proteinaceous substance, saccharide and hydrophobic amino acid having the hydropathy index of about not less than 2, wherein the concentration of the hydrophobic amino acid is in the range of 0.05 wt. % to less than 40 wt. % based on the total amount of the dry composition.Type: GrantFiled: February 25, 2000Date of Patent: January 8, 2002Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Chikamasa Yamashita, Masaaki Odomi
-
Publication number: 20010049361Abstract: Provisions of a foam inhibitor which effectively inhibits foaming (bubbling) caused at the time of dissolving dry compositions and of a water-soluble dry composition which comprises the foam inhibitor. The form inhibitor is suitable for inhibiting foaming caused at the time of dissolving dry compositions comprising saccharide which contain a hydrophobic amino acid as essential ingredient; and the water-soluble dry composition contains pharmacologically active proteinaceous substance, saccharide and hydrophobic amino acid having the hydropathy index of about not less than 2, wherein the concentration of the hydrophobic amino acid is in the range of 0.05 wt. % to less than 40 wt. % based on the total amount of the dry composition.Type: ApplicationFiled: July 12, 2001Publication date: December 6, 2001Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Chikamasa Yamashita, Masaaki Odomi
-
Patent number: 6303631Abstract: A water-soluble eye drop comprising (a) at least one selected from carteolol and an acid addition salt thereof, (b) at least one acrylic polymer selected from a straight-chain type polyacrylic acid and a pharmaceutically acceptable water-soluble salt thereof, and (c) at least one selected from a water-soluble alkali metal salt and a water-soluble amine. The water soluble eye drop has a remarkably long duration time of drug efficacy, and is superior in intraocular pressure inhibition action and is effective for treatment of glaucoma.Type: GrantFiled: June 21, 2000Date of Patent: October 16, 2001Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Yuji Sugahara, Kazuya Sakata, Masaaki Odomi
-
Patent number: 5445830Abstract: A highly absorbable pharmaceutical composition containing, as the active ingredient, methyl 3-phenyl-2(E)-propenyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate in an amorphous state and a pH-dependent type copolymer of methacrylic acid or its derivatives which composition has been prepared by dissolving the two components together in an organic solvent and thereafter removing the solvent.Type: GrantFiled: February 12, 1993Date of Patent: August 29, 1995Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Yoshihiro Ishizue, Kozo Ishida, Masaaki Odomi, Toru Nishibayashi, Kaszuyo Koshino